HRP20131052T1 - Agonisti mglu2 - Google Patents

Agonisti mglu2 Download PDF

Info

Publication number
HRP20131052T1
HRP20131052T1 HRP20131052AT HRP20131052T HRP20131052T1 HR P20131052 T1 HRP20131052 T1 HR P20131052T1 HR P20131052A T HRP20131052A T HR P20131052AT HR P20131052 T HRP20131052 T HR P20131052T HR P20131052 T1 HRP20131052 T1 HR P20131052T1
Authority
HR
Croatia
Prior art keywords
amino
bicyclo
hexane
triazol
ylsulfanyl
Prior art date
Application number
HRP20131052AT
Other languages
English (en)
Croatian (hr)
Inventor
James Allen Monn
Lourdes Prieto
Lorena Taboada Martinez
Carlos Montero Salgado
Bruce William Shaw
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20131052(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20131052T1 publication Critical patent/HRP20131052T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20131052AT 2009-12-21 2010-12-15 Agonisti mglu2 HRP20131052T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
HRP20131052T1 true HRP20131052T1 (hr) 2013-12-06

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131052AT HRP20131052T1 (hr) 2009-12-21 2010-12-15 Agonisti mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2540728T (lt) 2010-02-17 2019-06-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
AU2011329136B2 (en) * 2010-11-18 2014-11-06 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
SI2721012T1 (sl) 2011-06-17 2016-08-31 Eli Lilly And Company Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kisline kot agonisti mglu2 receptorja
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
CN109999025A (zh) 2014-01-21 2019-07-12 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
LT3277270T (lt) 2015-04-01 2022-01-10 Akebia Therapeutics, Inc. Kompozicijos ir būdai skirti anemijos gydymui

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
EP1351925A1 (en) * 2001-01-11 2003-10-15 Eli Lilly And Company Prodrugs of excitatory amino acids
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
EA011231B1 (ru) * 2002-06-11 2009-02-27 Эли Лилли Энд Компани Пролекарство возбуждающей аминокислоты и его применение
JP4984529B2 (ja) * 2003-06-26 2012-07-25 大正製薬株式会社 2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
AU2011329136B2 (en) * 2010-11-18 2014-11-06 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

Also Published As

Publication number Publication date
CN102695701A (zh) 2012-09-26
HK1171228A1 (en) 2013-03-22
ES2435651T3 (es) 2013-12-20
US8318184B2 (en) 2012-11-27
HN2012001160A (es) 2015-08-24
TN2012000281A1 (en) 2013-12-12
AU2010340039A1 (en) 2012-08-09
JP5779190B2 (ja) 2015-09-16
MX2012007332A (es) 2012-07-20
JP2013514974A (ja) 2013-05-02
SI2516406T1 (sl) 2013-11-29
AR079343A1 (es) 2012-01-18
US20110152334A1 (en) 2011-06-23
AU2010340039B2 (en) 2014-03-20
KR101395356B1 (ko) 2014-05-14
EP2516406B1 (en) 2013-09-18
CR20120322A (es) 2012-07-10
PT2516406E (pt) 2013-10-10
CA2784667C (en) 2014-11-18
DOP2012000173A (es) 2012-11-30
CN102695701B (zh) 2014-10-01
PE20121688A1 (es) 2012-12-05
KR20120094056A (ko) 2012-08-23
WO2011084437A1 (en) 2011-07-14
TW201144290A (en) 2011-12-16
CA2784667A1 (en) 2011-07-14
EA201290558A1 (ru) 2012-12-28
PH12012501253A1 (en) 2014-08-01
PL2516406T3 (pl) 2014-03-31
RS53063B (sr) 2014-04-30
EA020229B1 (ru) 2014-09-30
BR112012017188A8 (pt) 2016-10-04
JO2978B1 (en) 2016-03-15
BR112012017188B1 (pt) 2021-06-22
MY160618A (en) 2017-03-15
NZ600305A (en) 2014-01-31
ECSP12011989A (es) 2012-07-31
IL220011A (en) 2014-03-31
MA33824B1 (fr) 2012-12-03
IL220011A0 (en) 2012-07-31
DK2516406T3 (da) 2013-10-14
SG181836A1 (en) 2012-08-30
TWI477490B (zh) 2015-03-21
CY1114880T1 (el) 2016-12-14
UA107684C2 (xx) 2015-02-10
EP2516406A1 (en) 2012-10-31
BR112012017188A2 (pt) 2016-03-22

Similar Documents

Publication Publication Date Title
HRP20131052T1 (hr) Agonisti mglu2
ES2558477T3 (es) Triazoles sustituidos útiles como inhibidores de AXL
AU2020294196B2 (en) Estrogen receptor modulators
ES2442905T3 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurólógicos
ES2655527T3 (es) Derivados novedosos de amino pirimidina
ES2606752T3 (es) Método para la preparación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2- carboxamida
EP3740487B1 (en) Benzamide compounds as bci inhibitors for the treatment of hiv
ES2808988T3 (es) Composiciones y métodos para inhibir la actividad arginasa
KR102506324B1 (ko) 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
ES2670571T3 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
ES2811119T3 (es) Derivados de naftiridina como antagonistas de integrina alfa v beta 6 para el tratamiento de, por ejemplo, enfermedades fibróticas
AU2019264253B2 (en) Factor XIIa inhibitors
HRP20151218T1 (hr) Sredstva za induciranje apoptoze za lijeäśenje raka te imunih i autoimunih bolesti
JP2013514974A5 (enExample)
HRP20180746T4 (hr) Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
CA3058639A1 (en) Methods of using ehmt2 inhibitors
ES2784250T3 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
FI2291080T5 (fi) Uusia sfingosiinifosfaattireseptorimodulaattoreita
ES2662026T3 (es) Nuevo inhibidor de renina
RU2009133262A (ru) Нападизилатная соль антагониста мускаринового мз-рецептора
HRP20240361T1 (hr) Analozi benzoazepina kao sredstva za inhibiciju brutonove tirozin kinaze
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
BR112018014302A2 (en) 3- (carboxyethyl) -8-amino-2-oxo-1,3-diaza-spiro [4.5] decane derivatives
WO2022140555A1 (en) Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases
ES2343624T3 (es) Derivados de prolina que tienen afinidad por la subunidad alfa-2-delta del canal de calcio.